View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
May 29, 2020

Novo Nordisk’s semaglutide demonstrates superior weight loss versus placebo in STEP 4 trial

By Victoria Smith

At the beginning of May, Novo Nordisk announced positive topline results from its STEP 4 study, a Phase IIIa study investigating the use of its drug semaglutide to achieve sustained weight reduction for patients suffering from obesity. STEP 4 trial is a randomised, double-blind, multicenter, placebo-controlled, withdrawal trial investigating the use of the subcutaneously administered drug versus placebo.

The result is major for the worldwide obesity market, where Novo’s drug Saxenda (liraglutide) presently occupies a 55% market share. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena